These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34251122)

  • 1. Application of Ultrasound in the Assessment of Oligoarticular Psoriatic Arthritis Subset: Results from Patients Treated with Apremilast.
    Lucchetti R; Ceccarelli F; Cipriano E; Perricone C; Spinelli FR; Alessandri C; Conti F
    Isr Med Assoc J; 2021 Jul; 23(7):412-415. PubMed ID: 34251122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study.
    Ceccarelli F; Lucchetti R; Perricone C; Spinelli FR; Cipriano E; Truglia S; Miranda F; Riccieri V; Di Franco M; Scrivo R; Alessandri C; Valesini G; Conti F
    Clin Rheumatol; 2019 Nov; 38(11):3145-3151. PubMed ID: 31317423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score).
    Ficjan A; Husic R; Gretler J; Lackner A; Graninger WB; Gutierrez M; Duftner C; Hermann J; Dejaco C
    Arthritis Res Ther; 2014 Oct; 16(5):476. PubMed ID: 25361855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
    Strand V; Schett G; Hu C; Stevens RM
    J Rheumatol; 2013 Jul; 40(7):1158-65. PubMed ID: 23588944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early response to apremilast treatment in psoriatic arthritis: a real-life ultrasonographic follow-up study.
    Ceccarelli F; Lucchetti R; Spinelli FR; Perricone C; Truglia S; Miranda F; Scrivo R; Alessandri C; Valesini G; Conti F
    Rheumatology (Oxford); 2018 Aug; 57(8):1490-1491. PubMed ID: 29850865
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of mud-bath therapy in psoriatic arthritis patients treated with TNF inhibitors. Clinical evaluation and assessment of synovial inflammation by contrast-enhanced ultrasound (CEUS).
    Cozzi F; Raffeiner B; Beltrame V; Ciprian L; Coran A; Botsios C; Perissinotto E; Grisan E; Ramonda R; Oliviero F; Stramare R; Punzi L
    Joint Bone Spine; 2015 Mar; 82(2):104-8. PubMed ID: 25623520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study.
    Teoli M; Zangrilli A; Chimenti MS; Talamonti M; Bavetta M; Graceffa D; Perricone R; Chimenti S
    Clin Dev Immunol; 2012; 2012():823854. PubMed ID: 22649467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
    Gossec L; Coates LC; Gladman DD; Aelion JA; Vasandani J; Pinter A; Merola JF; Kavanaugh A; Reddy J; Wang R; Brunori M; Klyachkin Y; Deignan C; Mease PJ
    Ann Rheum Dis; 2024 Oct; 83(11):1480-1488. PubMed ID: 39164067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
    Favalli EG; Conti F; Selmi C; Iannone F; Bucci R; D'Onofrio F; Carlino G; Santo L; Semeraro A; Zuccaro C; D'Angelo S; Atzeni F; Marino F; Monti S; Guidelli GM; Spinelli FR; Biggioggero M; Caporali R
    Clin Exp Rheumatol; 2020; 38(1):19-26. PubMed ID: 31074721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).
    Qu X; Zhang S; Tao L; Song Y
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):799-805. PubMed ID: 26918950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal Study.
    Ceccarelli F; Cipriano E; Natalucci F; Perricone C; Olivieri G; Orefice V; Morello F; Alessandri C; Spinelli FR; Conti F
    Isr Med Assoc J; 2020 Jul; 22(7):415-419. PubMed ID: 33236565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis.
    Allard A; Antony A; Shaddick G; Jadon DR; Cavill C; Robinson G; Korendowych E; McHugh N; Tillett W
    Rheumatology (Oxford); 2019 Feb; 58(2):269-273. PubMed ID: 30247726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.